CD274 and non-small cell lung carcinoma: On the other hand, immunotherapy is not a recommended strategy for ALK-positive NSCLC patients, although PD-L1-positive rates among ALK-positive NSCLC patients are high, 46.7–50% and 13.3–16%, respectively [51].